Rigel Pharmaceuticals | RIGL - Cost Of Sales


Rigel Pharmaceuticals reported $8.03M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Amgen USD 1.6B 187M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD -204M 3.48B Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Veracyte USD 38.49M 794K Mar/2026